Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us? — Gianna Fabbri (2009) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Shared by
Aldo Maggioni
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Article
2009
en
Authors
GF
Gianna Fabbri
Aldo Maggioni
Related publications
Article
2014
LFP and oscillations—what do they tell us?
Karl Friston
,
André M. Bastos
,
Dimitris A. Pinotsis
,
Vladimir Litvak
Article
2023
Sample, Fuzzy and Distribution Entropies of Heart Rate Variability: What Do They Tell Us on Cardiovascular Complexity?
Paolo Castiglioni
,
Giampiero Merati
,
Gianfranco Parati
,
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Andrea Faini
Article
2010
A Tale of Two Depressions: What do the New Data Tell Us?
Barry Eichengreen
Article
2023
[What does excess mortality tell us?]
Olaf M. Dekkers
,
Mark de Boer
,
Frits R. Rosendaal
PubMed
Article
2024
Global variations in gallbladder cancer incidence: What do recorded data and national estimates tell us?
Marion Piñeros
,
Jérôme Vignat
,
Murielle Colombet
,
Mathieu Laversanne
,
Catterina Ferreccio
,
Katy Heise
,
Sharayu Mhatre
,
Jill Koshiol
,
Freddie Ian Bray
Discussion(0)
No comments yet. Be the first to comment.